LipidDoc_ATL said:

The pharmacokinetics explain nearly every practical question asked here.

Pushing back on LipidDoc_ATL here. I would resist the confidence. Half of what this board was certain about two years ago has since been quietly dropped, and nobody went back to correct the threads.

The figures, for anyone assembling their own picture. Numbers worth memorising for this class: Tmax one to three days for the weekly peptides, terminal half-life about a week for semaglutide and about five days for tirzepatide, steady state at four to five half-lives, subcutaneous bioavailability high enough that site choice is irrelevant.

That is the short version; the long version is somebody else's post.

mike_nyc said:

Half of what this board was certain about two years ago has since been quietly dropped, and nobody went back to correct the threads.

Coming at mike_nyc’s question from a different direction. Start from the measurement rather than the conclusion. Almost every disagreement here turns out to be two people measuring different things and comparing the numbers anyway.

Worth separating that from the pharmacology, which this thread keeps folding into the same question. They behave differently and the advice does not transfer.

A narrower follow-up, since the general answer is now clear:

Which effects tachyphylax and which persist, because the answer explains why tolerability improves while the appetite effect keeps working?

OP back with an update, since a thread like this is useless without one.

Update — tachyphylaxis to the gastric effect, persistence of the appetite effect. Two curves, and I had been watching the wrong one.